Longevity checkups: which startup is ahead?

Which startups really compete in longevity checkups?

Eight private companies deserve a place in the longevity checkup comparison, although only Neko Health and Function Health currently combine mass-market ambition, meaningful scale and a broad preventive-health product.

We include companies that collect several types of health data, interpret the results medically and give customers a plan for what to do next. That brings Neko Health, Function Health, Prenuvo, Superpower, Biograph, Human Longevity, Fountain Life and Mito Health into the field.

The boundaries matter. Prenuvo began as a whole-body MRI company, but its new membership now adds biomarkers and ongoing clinical guidance. Fountain Life mixes screening with treatments, yet its diagnostic programs remain a major part of the business. Human Longevity and Biograph target wealthier customers, but their products show what the most complete checkup looks like before cost and scale become constraints.

We exclude Ezra because Function acquired it. We also exclude InsideTracker, Lifeforce and biological-age testing companies whose main product is an interpretation layer, hormone program, supplement plan or single testing method. Traditional executive-health hospitals also sit outside the comparison unless they have built a distinct, scalable startup platform.

Funding figures come from company announcements and the latest available private-market databases. Neko’s newest round takes its cumulative funding above $1 billion. Function has raised roughly $350 million, Prenuvo about $275 million and Human Longevity around $409 million. Fountain Life’s reported total is approximately $108 million, while Superpower has publicly announced a $30 million Series A.

Startup	What the company sells	Approximate disclosed funding
Neko Health	One-hour clinic checkup covering skin, cardiovascular, metabolic and blood health	$1.02B
Human Longevity	MRI, genome sequencing, biomarkers and executive-health programs	$409M
Function Health	Recurring laboratory testing, health-data software and optional imaging	$350M+
Prenuvo	Whole-body MRI, biomarkers and preventive-health memberships	$275M
Fountain Life	Premium diagnostics, physician support and longevity treatments	$108M
Superpower	Annual biomarker testing, digital care and a health marketplace	At least $30M
Mito Health	Laboratory testing with AI and clinician-reviewed recommendations	$4M
Biograph	One-day preventive assessment with imaging, fitness testing and follow-up	Undisclosed

Is there a clear leader in longevity checkups today?

Neko Health is narrowly ahead in longevity checkups today, with Function Health close behind and Prenuvo leading a smaller MRI-focused lane.

Neko has built the clearest version of a checkup as a single product. More than 100,000 people have completed its one-hour visit across eight clinics in Sweden and the United Kingdom. Another 350,000 people have registered, and roughly 75% of customers book and prepay for the following year before leaving the clinic. Those numbers combine demand, completed usage and repeat intent in a way no competitor currently matches.

Function probably serves more people. The company describes its membership as numbering in the hundreds of thousands, and its website now reports more than 75 million laboratory results delivered. Function also has national distribution through more than 2,000 testing locations and has moved into imaging through Ezra. The missing piece is customer depth: Function has never published a comparable renewal rate, second-year completion rate or precise active-member count.

Prenuvo has completed more than 170,000 scans and operates roughly two dozen clinics. That gives Prenuvo greater cumulative imaging volume than Neko has completed checkups. However, Prenuvo still revolves around MRI, even after adding blood biomarkers and clinical guidance to its new memberships.

We therefore see a narrow top two rather than one dominant winner. Neko leads on the complete experience, repeat behavior and proprietary technology. Function leads on national reach and probable customer volume. Prenuvo remains the strongest specialist.

If you want more recent data on this point, please see our latest longevity market report.

Which longevity checkup startup has the most customers?

Function Health probably has the largest paying customer base in longevity checkups now, likely at least twice the size of Neko Health’s completed-member base.

Function had nearly 50,000 paying members in mid-2024 and later began describing its membership as numbering in the hundreds of thousands. Its current total of more than 75 million delivered laboratory results supports that claim. Even 200,000 members, the lowest reasonable reading of “hundreds of thousands,” would put Function at roughly twice Neko’s disclosed completed usage.

The 75 million figure needs context. Function gives members access to more than 160 annual laboratory results, split across an initial test and a follow-up later in the year. Dividing 75 million by 160 produces about 469,000 full annual packages, but that cannot be treated as a customer count. Panels have changed, some members order extras, and results accumulate over several years. The calculation simply confirms that Function’s scale has moved well beyond tens of thousands of users.

Prenuvo has completed more than 170,000 scans. That places Prenuvo in the same broad order of magnitude as Function’s probable customer base, although repeat scans mean the total does not necessarily represent 170,000 unique people.

Superpower’s website says 150,000 members, but the company previously described 150,000 people as a waitlist. Without a clean active-member disclosure, we treat the current figure as a marketing claim rather than a reliable operating metric.

Function wins the customer-volume question. The lead looks meaningful, though far smaller than the 75 million headline might initially suggest.

Which longevity checkup startup is growing fastest?

Neko Health is currently growing fastest because its completed checkups increased tenfold while the company was also building physical clinics.

Neko had completed 10,000 scans when it announced its previous funding round. Around 18 months later, as seen above, the total had passed 100,000. That works out to roughly 150% annualized growth in cumulative usage. More tellingly, Neko says the number of checkups completed during 2025 was six times the 2024 volume.

Function also grew extremely quickly. Its membership rose from nearly 50,000 to at least 200,000 over roughly 17 months, based on the company’s later “hundreds of thousands” description. That implies minimum growth of about four times. Function may have grown faster in absolute customer additions, but national laboratories made expansion much easier than opening new clinics.

Prenuvo had completed more than 150,000 scans when it opened its London clinic and reported more than 170,000 a few months later. As pointed out above, Prenuvo already operates at real commercial scale, but the latest increase looks closer to the low double digits than the multiples achieved by Neko and Function.

The operating difficulty changes how we read these numbers. Function can add customers through existing laboratory locations. Neko needs equipment, real estate, trained staff and clinical capacity in every city. Growing tenfold under those constraints is the strongest expansion evidence in the category.

Which startup has built the best longevity checkup?

Neko Health currently has the best integrated longevity checkup, while Biograph and Human Longevity offer deeper testing to a much smaller and wealthier audience.

A Neko visit covers skin mapping, cardiovascular measurements, body composition, metabolic health and blood markers. The customer receives the results and discusses them with a clinician during the same visit. Neko has also added visceral-fat measurement and Apple Health integration, allowing clinicians to combine the clinic snapshot with data collected between appointments.

Function goes much deeper into blood. Its $365 membership includes more than 160 annual laboratory results, with an initial panel followed by another round three to six months later. Members can then add MRI, CT, multi-cancer blood tests and other diagnostics. The resulting coverage can exceed Neko’s, but the customer moves between separate laboratories, imaging centers and digital reports.

Prenuvo sees areas that Neko cannot. Its MRI scans the brain, spine and internal organs without ionizing radiation. Prenuvo’s new memberships add blood biomarkers and clinical support, bringing the product closer to a full preventive checkup. The core experience still begins with imaging, and MRI cannot replace skin examination, blood testing or standard cancer-screening programs.

Biograph and Human Longevity go further. Biograph’s $15,000 program combines more than 30 assessments, including whole-body MRI, coronary CT angiography, brain testing, a multi-cancer blood test and mid-year laboratory follow-up. Human Longevity’s $8,000 program includes whole-body and brain MRI, genome sequencing, cardiac imaging and hundreds of biomarkers.

Those premium programs win on depth. Neko wins on product design because it fits several useful measurements and a real clinical conversation into a repeatable one-hour visit at a price that a much broader group can consider.

If you want more recent data on this point, please see our latest longevity market report.

Which longevity startup can actually serve people at scale?

Function Health has the strongest nationwide delivery model, while Neko Health still has the biggest gap between customer demand and available appointments.

Function uses more than 2,000 existing laboratory locations across the United States. Its standard membership is available in every state except New York and New Jersey, and Function can add a member without opening a clinic or installing its own medical equipment.

Superpower follows the same asset-light model. Members can use more than 3,000 Quest Diagnostics locations or pay extra for an at-home draw. Superpower therefore has wider theoretical access than Neko, Prenuvo, Biograph, Fountain Life and Human Longevity combined.

Prenuvo has built the largest dedicated physical network. The company operates in the United States, Canada, Australia and the United Kingdom, with more than 200 healthcare professionals supporting the service. Prenuvo’s footprint gives the company more control than Function has over imaging, while avoiding the scarcity that still surrounds Neko appointments.

Neko operates six British clinics and two Swedish clinics, with New York scheduled to open in the autumn. Its registrations are roughly 3.5 times the number of completed visits. That ratio shows both impressive demand and a serious supply bottleneck. Neko’s newest capital should help, but opening clinics across the United States will require regulatory work, hiring, equipment servicing and consistent clinical operations.

Function wins on practical reach. Neko may eventually build the more controlled network, but the company first has to make appointments far easier to obtain.

Which longevity checkup gives customers the best value?

Neko Health offers the best value for an integrated clinic checkup, while Superpower currently offers the lowest credible entry price.

Neko charges £299 in the United Kingdom. That price covers several measurement types, proprietary imaging and a clinician discussion during the same visit. Neko leaves out whole-body MRI and genome sequencing, but most competing clinic programs charge several thousand dollars before reaching that level of integration.

Function remains the strongest laboratory deal. Customers receive more than 160 annual results for $365. Function originally promoted a $499 MRI after acquiring Ezra, but current pages show different prices, including $899 on one campaign and $999 in the main FAQ. We therefore use $899 to $999 as the present range rather than repeating the earlier launch price.

Superpower recently cut its annual price to $199. The membership includes one yearly collection covering more than 100 biomarkers, a personalized plan and care-team access. That is unusually cheap, though customers pay separately for repeat testing, home collection and many follow-up products.

Fountain Life has also started moving downmarket. Its new $595 BASE plan is a major change for a company previously associated with annual memberships starting above $10,000. The lower tier gives Fountain Life a credible entry product, but its expensive imaging and treatment programs remain separate.

Startup or program	Current public starting price	What the customer gets	Our value judgment
Superpower	$199 per year	100+ biomarkers, plan and care-team access	Cheapest serious entry point
Neko Health	£299 per visit	Skin, heart, blood, metabolic and body-composition checkup	Best integrated value
Function Health	$365 per year	160+ annual laboratory results	Best laboratory value
Fountain Life BASE	$595 per year	Lower-cost preventive-health membership	Interesting new downmarket offer
Function with MRI	About $1,264 to $1,364 combined	Laboratory membership plus current MRI pricing	Broad coverage below premium-clinic prices
Prenuvo	About $2,500 for its flagship scan	Whole-body MRI and results review	Strong imaging, high price
Biograph Core	$7,500 per year	20+ assessments and whole-body MRI	Deep testing for wealthy customers
Human Longevity Executive Health	$8,000 per year	MRI, genome, cardiac tests and biomarkers	Most data-heavy premium package
Biograph Black	$15,000 per year	30+ assessments and year-round oversight	Exceptional depth, very narrow audience

If you want more recent data on this point, please see our latest longevity market report.

Which longevity startup keeps customers coming back?

Neko Health has the strongest retention evidence in longevity checkups by a wide margin.

Neko currently says about 75% of customers book and prepay for the following year before leaving their appointment. When Neko had completed only 10,000 checkups, the equivalent figure was around 80%. The rebooking rate therefore stayed within five percentage points while cumulative usage grew tenfold.

That stability is more useful than the latest percentage by itself. Early customers are often unusually enthusiastic, so retention commonly drops as a product reaches a broader audience. Neko’s reported repeat intent remained high after expansion from Stockholm into several British cities.

The company has also analyzed 1,469 people who completed a second visit about one year later. That confirms that at least part of the prepaid cohort returned and completed another checkup. The study does not tell us what share of all first-year customers eventually attended, but it gives Neko another layer of evidence beyond bookings.

Function and Superpower automatically sell annual memberships, yet neither company publishes renewal cohorts, second-year testing completion or cancellation rates. Prenuvo only launched its structured membership recently, so meaningful renewal data cannot exist yet.

Neko’s lead here is unusually clear. Function may have more members, but Neko has shown that customers want the experience again after trying it.

Which longevity checkup startup has the strongest clinical evidence?

Prenuvo currently has the strongest clinical-research program, although no longevity checkup startup has proved that its complete service helps people live longer.

Prenuvo says it has contributed to more than 50 publications and abstracts and has built one of the world’s largest whole-body screening MRI datasets. Its Polaris analysis followed 1,011 mostly asymptomatic people. Potential cancers were flagged in 41 participants, and follow-up information produced an overall cancer-detection rate of roughly 2.2%.

The same results show why more research is needed. About 4.9% of participants were sent for biopsy, while 2.2% were ultimately found to have cancer. The remaining 2.7% underwent a biopsy without a cancer diagnosis. Some cancers found by screening may also grow so slowly that early discovery never changes the outcome.

Prenuvo has launched a long-term prospective study to examine whole-body MRI more systematically. That gives the company a stronger research pathway than competitors relying mainly on customer stories or internal detection totals. Medical reviews still conclude that evidence for screening healthy, average-risk people remains incomplete, particularly around mortality, cost-effectiveness and unnecessary follow-up.

Neko has produced useful longitudinal evidence from 1,469 returning customers. Blood pressure, cholesterol and blood sugar improved across parts of that cohort. Neko openly describes the work as company data rather than a randomized clinical trial, and there was no control group. Lifestyle changes, medication and the characteristics of people who chose to return could explain part of the improvement.

Function, Superpower and the premium clinics share examples of serious conditions found through testing. Those stories can be genuine and important, but they do not reveal how often testing causes unnecessary anxiety, repeat procedures or treatment without better long-term outcomes.

Prenuvo wins the research comparison. The broader medical case for routine longevity checkups remains open.

Which longevity startup has the strongest competitive moat?

Neko Health has built the hardest longevity checkup product to copy, while Function Health has the most promising data and distribution advantage.

Neko controls the hardware, software, clinic workflow and customer experience. Every visit captures standardized skin images, cardiovascular measurements, blood results and body-composition data through the same system. Reproducing it requires far more than another health dashboard. A competitor would need to develop equipment, validate the workflow and operate clinics consistently.

Function’s moat comes from reach and data. More than 75 million laboratory results can support better longitudinal comparisons, recommendations and risk models. Function can also connect laboratory histories with imaging, medical records and wearables through its Medical Intelligence Lab. However, the underlying tests are supplied by third parties and can be ordered by other companies. Function must make its interpretation and user experience much better than those alternatives.

Prenuvo has developed screening-specific MRI protocols, specialist radiology workflows and a large imaging dataset. More than 200 medical professionals work within its affiliated clinical group. That knowledge is valuable, although established imaging networks already own MRI machines and employ radiologists. Prenuvo’s brand, protocols and longitudinal database need to keep producing a better experience than those incumbents.

Human Longevity has another credible moat: genome data combined with imaging and deep phenotyping. The company has spent more than a decade collecting complex health information. Its limited locations and high pricing have kept that scientific depth from creating a broad consumer network.

Neko has the strongest moat today because its advantage sits inside both the technology and the delivery system. Function could catch up if its much larger flow of longitudinal data produces recommendations or early-detection performance that customers cannot get elsewhere.

If you want more recent data on this point, please see our latest longevity market report.

Which longevity startup has used its funding most efficiently?

Function Health appears to have used venture capital most efficiently so far, while Neko Health now has by far the strongest financial position.

A rough funding-to-adoption comparison makes the difference visible. Neko has raised about $1.02 billion, equivalent to roughly $10,000 for every disclosed completed checkup. Function has raised around $350 million, or less than $1,800 for every member if we use 200,000 as the minimum interpretation of “hundreds of thousands.” Prenuvo sits near $1,600 of funding for every completed scan.

These ratios say nothing about gross margin, acquisition costs or profitability. Neko also raised most of its money after proving the product, which means much of the latest capital has not yet been converted into clinics or customers. The calculation mainly shows how differently the companies are built.

Function connects customers to infrastructure that already exists. Prenuvo needs expensive imaging capacity, but it can use a mix of owned and partner sites. Neko builds proprietary equipment and a dedicated clinical environment for every location.

Function therefore leads on visible capital efficiency. Neko has chosen a much more expensive route, and investors have given the company enough money to test that strategy properly. The judgment could reverse if Neko’s new clinics generate high appointment volumes and stable repeat revenue.

Which longevity checkup startup has the strongest momentum now?

Neko Health has the strongest momentum now, while Function Health is broadening its platform fastest and Superpower is pushing prices down hardest.

Neko has just raised $700 million at a valuation reported near $7 billion. The company is preparing its New York opening, developing more US locations and has recently added visceral-fat measurement, body-fat analysis and wearable integration. The latest round is the third major financing in three years, following $65 million and $260 million rounds.

Function’s recent moves form a clear sequence. The company acquired Ezra, lowered its laboratory membership from $499 to $365, added faster MRI and CT access, raised $298 million and launched a research group focused on combining different forms of medical data. Function is steadily turning a laboratory membership into a broader preventive-health platform.

Prenuvo is moving in the opposite direction from the same starting point. The company began with MRI and has now added biomarker tracking, ongoing clinical guidance and annual memberships. Prenuvo also opened its first European clinic and recently crossed 170,000 completed scans.

Superpower reduced its entry price from $499 to $199, acquired Base and Feminade, and is expanding into prescriptions, care coordination and health products. The price cut could produce much faster adoption, although Superpower still needs to show that a $199 membership can support laboratory costs, clinical staff and customer acquisition.

Fountain Life’s new $595 membership adds another recent clue. Premium providers are trying to reach customers who will never spend $10,000 or more on annual diagnostics.

Neko’s newest financing gives it a much larger expansion budget than any direct rival. Function’s recent product moves may matter more over time if the company makes imaging as easy to access as its blood tests.

Has any longevity checkup startup moved beyond wealthy self-pay customers?

No longevity checkup startup has yet turned comprehensive preventive testing into a routine insured or employer-funded benefit.

Most leading products qualify for health savings or flexible spending accounts, but customers still pay the underlying bill. Function, Superpower and Prenuvo advertise HSA or FSA eligibility. Neko has not announced broad insurance coverage for its coming US service.

The companies are building distribution relationships around the edges. Function has promoted discounted memberships through Equinox. Prenuvo has partnerships with Baker Health and Parsley Health. Superpower markets programs to employers and health plans, while Fountain Life says it is discussing integration with healthcare providers.

Those relationships expand access, but none proves that an insurer or large employer is paying for the complete checkup at scale. No disclosed contract covers hundreds of thousands of employees, no major reimbursement code applies to the full service, and there is no evidence yet that repeat screening has reduced an employer’s medical spending.

That commercial gap helps explain why consumer branding matters so much in this market. Customers are buying preventive testing with their own money, often before medical guidelines or insurance policies support it.

The first company to secure broad employer or insurer coverage could change the ranking quickly. Function’s distributed model looks easiest to package as a benefit. Neko’s standardized visit may be more appealing if the company can prove better outcomes and predictable downstream costs.

What could make Neko Health lose its longevity checkup lead?

Neko Health could lose its lead through a slow US rollout, while Function Health faces a harder question around retention and the medical value of very broad testing.

Neko’s demand already exceeds its clinic capacity. The company must now reproduce an eight-clinic European operation across a much larger, more regulated US market. New York is only the first test. Delays in approvals, hiring, equipment deployment or clinician training could allow Function to build a nationwide combined lab-and-imaging product first.

Neko also needs stronger clinical proof. Its repeat-customer data is encouraging, but a self-selected group without a control population cannot show how much the checkup itself improved health. Investors are now valuing Neko like a future global healthcare platform, so observational results and strong customer satisfaction will eventually become insufficient.

Function’s risk sits closer to the product. Testing more than 160 markers will naturally uncover more values outside standard ranges. A recent analysis of almost two billion longitudinal laboratory measurements found that overly personalized reference ranges could classify as many as 68% of results as abnormal without a matching link to adverse outcomes. Function needs to show that more data produces better decisions rather than more worry and follow-up spending.

Function also needs to publish renewal data. Rapid customer acquisition can hide weak long-term engagement, especially when the first year delivers the novelty of an unusually large test panel. Neko has shown repeat commitment; Function has not yet given us the same visibility.

Prenuvo faces price and evidence pressure. Whole-body MRI can find serious disease, but medical researchers still debate routine screening for average-risk, symptom-free adults. Function is now advertising much cheaper MRI access, while Prenuvo’s flagship scan remains around $2,500.

Superpower’s challenge is economic. A $199 annual fee has to cover a broad laboratory panel, technology, clinical support and customer acquisition. Add-on tests, prescriptions and marketplace sales may become necessary for attractive margins.

Each leader therefore has a different weakness. Neko must build clinics quickly, Function must prove that members stay and benefit, and Prenuvo must defend a premium price while the evidence matures.

Which longevity checkup startups are actually ahead?

Neko Health is currently the best longevity checkup startup overall, but Function Health is close enough to take the lead if national distribution turns into strong repeat usage.

We give Neko first place because the company has built the clearest complete product. The visit combines several useful measurement types, same-day interpretation, proprietary technology and unusually strong rebooking. Customers appear to understand what they are buying and want to do it again.

Function takes second place because its customer reach may already be several times larger. Function is cheaper, easier to access and better positioned to collect frequent blood data. The Ezra acquisition also closes part of the gap in imaging. We keep Function behind Neko because its active membership, renewal behavior and imaging adoption remain unclear.

Prenuvo ranks third. The company has completed more preventive MRI scans than any direct challenger, built an international clinic network and created the strongest research program in the group. Prenuvo’s higher price and imaging-heavy product keep it behind the two broader platforms.

Superpower ranks fourth because the company combines national availability with the lowest entry price. Its next test is credibility at scale: active-member disclosure, renewals, medical outcomes and sustainable economics.

Human Longevity and Biograph offer more complete individual assessments than the mass-market leaders. Their prices and small physical footprints place them in premium executive health rather than the center of the startup race. Fountain Life has a larger clinic network and is moving downmarket, but treatments and expensive memberships still shape much of its positioning. Mito Health remains early.

Neko’s lead is real but narrow. Function could move into first place by publishing strong retention, scaling its imaging network and showing that customers actually use the combined platform year after year. Neko can widen the gap by opening US clinics quickly without losing its current rebooking rate or same-visit quality.

Rank	Startup	Why the startup holds this position
1	Neko Health	Best integrated checkup, strongest disclosed repeat behavior, proprietary technology and the most powerful recent momentum
2	Function Health	Probable customer-volume leader, nationwide laboratory access, strong pricing and a rapidly expanding imaging platform
3	Prenuvo	Clear leader in preventive whole-body MRI, with 170,000+ completed scans, international reach and the best research program
4	Superpower	Cheapest credible national option, strong early reach and aggressive product expansion, but limited verified operating disclosure
5	Human Longevity	Deepest combination of genomics, imaging and biomarkers, held back by high prices and a small clinic footprint
6	Biograph	Excellent premium assessment and physician-led follow-up, but only two locations and little disclosed commercial data
7	Fountain Life	Broad diagnostics and a growing clinic network, though premium treatments and pricing weaken the direct comparison
8	Mito Health	Accessible laboratory-first model with credible early backing, but still too small and lightly funded to challenge the leaders

If you want more recent data on this point, please see our latest longevity market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.